Literature DB >> 10914553

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.

W G An1, S G Hwang, J B Trepel, M V Blagosklonny.   

Abstract

Inhibitors of proteases are currently emerging as a potential anti-cancer modality. Nonselective protease inhibitors are cytotoxic to leukemia and cancer cell lines and we found that this cytotoxicity is correlated with their potency as inhibitors of the proteasome but not as inhibitors of calpain and cathepsin. Highly selective inhibitors of the proteasome were more cytotoxic and fast-acting than less selective inhibitors (PS341>>ALLN>>ALLM). Induction of wt p53 correlated with inhibition of the proteasome and antiproliferative effect in MCF7, a breast cancer cell line, which was resistant to apoptosis caused by proteasome inhibitors. In contrast, inhibitors of the proteasome induced apoptosis in four leukemia cell lines lacking wt p53. The order of sensitivity of leukemia cells was: Jurkat>HL60> or =U937>>K562. The highly selective proteasome inhibitor PS-341 induced cell death with an IC50 as low as 5 nM in apoptosis-prone leukemia cells. Cell death was preceded by p21WAF1/CIP1 accumulation, an alternative marker of proteasome inhibition, and by cleavage of PARP and Rb proteins and nuclear fragmentation. Inhibition of caspases abrogated PARP cleavage and nuclear fragmentation and delayed, but did not completely prevent cell death caused by PS-341. Reintroduction of wt p53 into p53-null PC3 prostate carcinoma cells did not increase their sensitivity to proteasome inhibitors. Likewise, comparison of parental and p21-deficient cells demonstrated that p21WAF1/CIP1 was dispensable for proteasome inhibitor-induced cytotoxicity. We conclude that accumulation of wt p53 and induction of apoptosis are independent markers of proteasome inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914553     DOI: 10.1038/sj.leu.2401812

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen.

Authors:  Patricia A Eisenach; Pedro Corrêa de Sampaio; Gillian Murphy; Christian Roghi
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

2.  The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Authors:  Azmi Yerlikaya; Emrah Okur; Engin Ulukaya
Journal:  Tumour Biol       Date:  2012-04-04

Review 3.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

Review 4.  New drugs in acute myeloid leukemia.

Authors:  Francis J Giles
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

5.  Proteasome inhibitors suppress the protein expression of mutant p53.

Authors:  Marianna Halasi; Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin.

Authors:  Yun Li; John E Shively
Journal:  Exp Cell Res       Date:  2013-03-07       Impact factor: 3.905

7.  The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.

Authors:  A Milano; F Perri; F Caponigro
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

8.  Targeted therapy in melanoma.

Authors:  Hussein Tawbi; Neelima Nimmagadda
Journal:  Biologics       Date:  2009-12-29

Review 9.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Authors:  Duonan Yu; Martin Carroll; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.